Vir Biotechnology (NASDAQ:VIR) Director Sells $128,480.00 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki Sato sold 22,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $5.84, for a total transaction of $128,480.00. Following the sale, the director directly owned 1,232,391 shares of the company’s stock, valued at approximately $7,197,163.44. This trade represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Vir Biotechnology Trading Down 0.7%

Shares of Vir Biotechnology stock opened at $5.66 on Friday. The company has a fifty day moving average price of $4.99 and a 200 day moving average price of $5.35. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $14.45. The stock has a market cap of $786.29 million, a price-to-earnings ratio of -1.42 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The business had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $2.38 million. During the same period last year, the company posted ($1.02) earnings per share. The firm’s revenue for the quarter was down 60.5% on a year-over-year basis. Analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Hedge Funds Weigh In On Vir Biotechnology

Several large investors have recently modified their holdings of VIR. Raymond James Financial Inc. bought a new position in shares of Vir Biotechnology during the second quarter worth about $35,000. GAMMA Investing LLC lifted its position in shares of Vir Biotechnology by 524.3% during the first quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock worth $46,000 after purchasing an additional 5,972 shares during the last quarter. Apollon Wealth Management LLC bought a new position in shares of Vir Biotechnology during the second quarter worth about $50,000. Daiwa Securities Group Inc. lifted its position in shares of Vir Biotechnology by 2,200.6% during the second quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock worth $62,000 after purchasing an additional 11,773 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in shares of Vir Biotechnology during the second quarter worth about $63,000. Institutional investors own 65.32% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on VIR. Bank of America raised shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and upped their price objective for the company from $12.00 to $14.00 in a research report on Wednesday, August 27th. Raymond James Financial began coverage on shares of Vir Biotechnology in a research report on Friday, July 11th. They issued an “outperform” rating for the company. Evercore ISI began coverage on shares of Vir Biotechnology in a research report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a research report on Monday, September 15th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and an average price target of $17.30.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).